Target intelligence / Profile preview

Long intergenic non-protein coding RNA 842 (LINC00842)

Target
LINC00842
Molecular classification
Long non-coding RNA (lncRNA), Other (Regulatory RNA)
01

Overview

Long intergenic non-protein coding RNA 842 (LINC00842) is a long non-coding RNA molecule that has no protein-coding potential and mainly functions as a regulatory RNA. It is upregulated in pancreatic ductal adenocarcinoma (PDAC) and drives malignant cellular phenotypes including proliferation, migration, invasion, and metabolic reprogramming. Mechanistically, LINC00842 interacts with the transcriptional co-activator PGC-1α, preventing its deacetylation by SIRT1, which leads to a metabolic shift favoring fatty acid synthesis over mitochondrial oxidative metabolism. High levels of LINC00842 and acetylated PGC-1α are correlated with poor patient survival in PDAC. LINC00842 is considered a potential therapeutic target, and silencing it or inhibiting its downstream metabolic effectors suppresses tumor progression in preclinical models. It appears to have tissue-specific functions that may also play roles in other cancer types

Other names
LINC00842Long intergenic non-protein coding RNA 842
02

Mechanism of action

For experimental interventions: RNA interference (RNAi) or antisense oligonucleotides (ASOs) targeting LINC00842 decrease tumor growth, proliferation, migration, and invasion; Inhibition of downstream metabolic targets (e.g., fatty acid synthase) represses tumor growth when LINC00842 levels are high; Mechanistic action: Disruption of LINC00842 binding to PGC-1α alters its acetylation state and metabolic gene programs

03

Biological functions

Regulation of cellular metabolismModulation of transcription co-regulator activityPromotes cell proliferationPromotes cell migration and invasionMetabolic reprogramming (switching to fatty acid synthesis from mitochondrial oxidative metabolism)Regulation of gene expression (impacts metabolic, anabolic, and catabolic genes)
04

Disease associations

Cancer (specifically Pancreatic ductal adenocarcinoma, PDAC)Possibly other cancer types (based on its induction by TGF-β in hepatocarcinoma and lung adenocarcinoma cell lines)
05

Safety considerations

Therapeutic targeting of lncRNAs is in preclinical stages; delivery, specificity, and off-target effects remain challengesBroad expression and function in multiple tissues suggest potential for unintended effects
06

Interacting drugs

No clinically approved drugs directly target LINC00842 yet.

1 more in the full profile.

07

Biomarkers

High LINC00842 expression level (biomarker for poor prognosis in PDAC patients)Elevated acetylated PGC-1α correlates with LINC00842 upregulation in PDAC

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 842 (LINC00842).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 842 (LINC00842).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call